Hashimoto thyroiditis. Autoimmune thyroiditis
Conditions
Interventions
Intervention 1: The first intervention group will receive Selenium 200 micrograms tablet daily by mouth, for 3 to 6 months. Selenium tablets will be prepared from Sodium Selenate from Merck company by
Treatment - Drugs
The first intervention group will receive Selenium 200 micrograms tablet daily by mouth, for 3 to 6 months. Selenium tablets will be prepared from Sodium Selenate from Merck company by Shiraz school o
The second intervention group will receive 500 milligrams tablet of Vitamin C daily, by mouth, for 3 to 6 months. Vitamin C tablets will be prepared by Avicenna company
The control group will receive one tablet of placebo which will contain starch and will be similar to the real drugs. The placebo tablets will be prepared by Shiraz school of pharmacy
Sponsors
Research Vice-Chancellor of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age, 15 years old or more; anti-thyroid peroxidase antibody titer 200 units per liter or more. Exclusion criteria: pregnant women; previous history of thyroid disorders; previous history of hypothalamo-hypophyseal disorders; presence of nonthyroidal disorders (such as renal; hepatic; cardiovascular disorders; diabetes mellitus; infectious diseases; renal stone; etc) ; consumption of drugs with effect on thyroid hormones metabolism; consumption of sex hormones; glucocorticoids; vitamins or supplements
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Titer of anti-thyroid peroxidase antibody. Timepoint: Before and after 3 to 6 months of treatment. Method of measurement: Measurement of anti-thyroid peroxidase antibody titer in serum by radioimmunoassay method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Thyroid function test including: thyroxine, thriiodothyronine, and thyroid stimulating hormone levels. Timepoint: Before treatment and after completion of treatment course. Method of measurement: Measurement of serum levels of hormones by immunoradiometric assay method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Fariba Karimi
Shiraz University of Medical Sciences
Outcome results
None listed